transcutaneous auricular neurostimulation (tAN)

DEVICE4 trials

Sponsors

Spark Biomedical, Inc., Medical University of South Carolina, Erin Takemoto, Texas Christian University

Conditions

Alcohol WithdrawalAuricular StimulationOpioid WithdrawalOpioid-use DisorderPMDDPerimenopause

Unknown Phase

Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal

CompletedNCT04075214

Spark Biomedical, Inc.Opioid-use Disorder, Opioid Withdrawal

Start: 2019-11-19End: 2020-12-14Updated: 2021-08-19

Mastoid taVNS-fMRI

CompletedNCT06518356

Medical University of South CarolinaAuricular Stimulation

Start: 2024-08-26End: 2025-04-28Updated: 2025-07-04

Use of tAN® in Alcohol Withdrawal Management

TerminatedNCT06771037

Erin TakemotoAlcohol Withdrawal

Start: 2025-04-21End: 2025-12-15Updated: 2026-08-05

Transcutaneous Auricular Neurostimulation (tAN) for Premenstrual Dysphoric Disorder (PMDD) and Perimenopause

RecruitingNCT07688720

Texas Christian UniversityPerimenopause, PMDD

Start: 2026-06-01End: 2027-03-01Target: 20Updated: 2026-07-07

Related Papers

Delivering transcutaneous auricular neurostimulation (tAN) to improve symptoms associated with opioid withdrawal: results from a prospective clinical trial.

2022-08-189 citations